- GlobeNewswire•12 hours agoRexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of Docetaxel for the Targeted Treatment of Solid Tumors
Rexahn’ s proprietary nanotechnology drug conjugate platforms optimize chemotherapy effectiveness and reduce side effect liability ROCKVILLE, Md., Oct. 26, 2016-- Rexahn Pharmaceuticals, Inc., a clinical ...
- Investopedia•15 days ago
Rexahn Pharmaceuticals has seen its shares fall sharply over the last month. Can its latest trial data offer optimism for a rally?
- GlobeNewswire•17 days agoRexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress
RX-3117 showed Preliminary Efficacy in Pancreatic Cancer Patients for Whom Three or More Prior Therapies had been Ineffective. Supinoxin™ was Safe and Well Tolerated in Patients with Advanced and Metastatic ...
Rexahn Pharmaceuticals, Inc. (RNN)
NYSE MKT - NYSE MKT Real Time Price. Currency in USD
|Bid||0.17 x 500|
|Ask||0.17 x 100|
|Day's Range||0.17 - 0.18|
|52wk Range||0.16 - 0.52|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.62|
|Avg Vol (3m)||915,881|
|Dividend & Yield||N/A (N/A)|